York Pharma PLC

While Bristol-Myers Squibb has been at the forefront of immuno-oncology, the big pharma has lagged behind competitors in some other therapeutic areas. The New York pharma is aiming to correct that by

Already very active in deal-making for fibrotic disease companies and candidates in the past year, Bristol-Myers Squibb ponied up $150m in upfront cash on Aug. 31 for an option to acquire Promedior In

The FDA has granted a priority review to Pfizer's new drug application (NDA) for palbociclib as a first-line therapy in combination with letrozole as a first-line treatment for postmenopausal women wi

The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (